top of page



  1. Amant F, Mirza MR, Koskas M, Creutzberg C. Cancer of the corpus uteri. Int J GynecolObstet. 2018;143: 37-50.

  2. Kurman RJ, Carcangiu ML, Herrington S, Young RH. Tumours of the Female Reproductive Organs. WHO classification of tumours. Lyon: IARC Press; 2014.

  3. Morice P, Leary A, Creutzberg C, et al. a, Endometrial cancer. The Lancet. 2016; 387(10023), 1094-1108.

  4. Karlsson B, Granberg S, Wikland M, et al. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding. A Nordic multicenter study. Am J Obstet Gynecol. 1995; 172:1488–1494.

  5. Timmermans A, Opmeer BC, Khan KS, et al. Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis. ObstetGynecol 2010; 116: 160–67.

  6. Akbayir O, Corbacioglu A, Numanoglu C, et al. Preoperative assessment of myometrial and cervical invasion in endometrial carcinoma by transvaginal ultrasound. GynecolOncol 2011; 122: 600–03.

  7. Jantarasaengaram S, Praditphol N, Tansathit T, Vipupinyo C, Vairojanavong K. Three-dimensional ultrasound with volume contrast imaging for preoperative assessment of myometrial invasion and cervical involvement in women with endometrial cancer. Ultrasound ObstetGynecol 2014; 43: 569–74.

  8. Kitajimaa et al. Value of fusion of PET and MRI for staging of endometrial cancer: Comparison with 18F-FDG contrast-enhanced PET/CT and dynamic contrast-enhanced pelvic MRI. European Journal of Radiology 82 (2013) 1672–1676.

  9. Jacobs I, Gentry-Maharaj A, Burnell M, et al. Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: A case-control study within the UKCTOCS cohort. Lancet Oncol. 2011; 12:38–48.

  10. Krishnamurti U, Movahedi-Lankarani S, Birdson G, et al. Protocol for the examination of specimens from patients with carcinoma and carcinosarcoma of the endometrium. College of American Pathologists. 2018.

  11. Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma: more than two types. LancetOncol 2014; 15: e268–78.

  12. Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, treatment and follow-up. Ann Oncol. 2016; 27:16–41.

  13. Janda M, Gebski V, Davies LC, et al. Effect of total laparoscopic hysterectomy vs total abdominal hysterectomy on disease-free survival among women with Stage I endometrial cancer: A randomized clinical trial. JAMA. 2017; 317:1224–1233.

  14. Lu Q, Liu H, Liu C, et al. Comparison of laparoscopy and laparotomy for management of endometrial carcinoma: a prospective randomized study with 11-year experience. J Cancer Res ClinOncol 2013; 139: 1853–59.

  15. Mariani A, Dowdy SC, Cliby WA, et al. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. GynecolOncol 2008; 109: 11–18.

  16. Beesley VL, Rowlands IJ, Hayes SC, et al, and the Australian National Endometrial Cancer Study Group. Incidence, risk factors and estimates of a woman’s risk of developing secondary lower limb lymphedema and lymphedema-specific supportive care needs in women treated for endometrial cancer. GynecolOncol 2015; 136: 87–93.

  17. Rossi EC, Kowalski LD, Scalici J, et al. A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): A multicentre, prospective, cohort study. Lancet Oncol. 2017; 18:384–392.

  18. Soliman PT, Westin SN, Dioun S, et al. A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. GynecolOncol. 2017; 146:234–239.

  19. Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: Multicentrerandomised trial. PORTEC Study Group. Postoperative radiation therapy in endometrial carcinoma. Lancet. 2000; 355:1404–1411.

  20. Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): An open-label, non-inferiority, randomised trial. Lancet. 2010; 375:816–823.

  21. Wortman BG, Creutzberg CL, Putter H, et al. PORTEC Study Group. Ten-year results of the PORTEC-2 trial for high-intermediate  risk endometrial carcinoma: improving patient selection for adjuvant therapy. Br J Cancer. 2018 Oct;119(9):1067-1074.

  22. Small W, Mell KL, Anderson P, et al. Clinical investigation uterus consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. Int. J. Radiation Oncology Biol Phys, 2008;71:428-434.

  23. Emons G, Tempfer C, Battista MJ, et al. Statement of the Uterus Committee of the Gynaecological Oncology Working Group (AGO) on the PORTEC-3 study. GeburtshilfeFrauenheilkd. 2018 Oct;78(10):923-926.

  24. De Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): Final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19: 295–309.

  25. Humber CE, Tierney JF, Symonds RP et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol 2007; 18: 409–420.

  26. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013.

  27. IARC Working Group. Human Papillomaviruses: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Lyon: International Agency forResearchonCancer; 2007:90.

  28. Hricak H, Gatsonis C, Chi DS, et al. Role of imaging in pretreatment evaluation of early invasive cervical cancer: Results of the intergroup study American College of Radiology Imaging Network 6651-Gynecologic Oncology Group 183. J ClinOncol. 2005; 23:9329–9337.

  29. Matsuo K, Machida H, Mandelbaum RS, et al. Validation of the 2018 FIGO cervical cancer staging system. GynecolOncol. 2019 Jan;152(1):87-93.

  30. Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynaecol Obstet. 2018 Oct;143Suppl 2:22-36.

  31. Delgado G, Bundy B, Zaino R, et al. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. GynecolOncol 1990;38:352-357.

  32. Kinney WK, Alvarez RD, Reid GC, et al. Value of adjuvant wholepelvis irradiation after Wertheim hysterectomy for early-stage squamous carcinoma of the cervix with pelvic nodal metastasis: A matched-control study. GynecolOncol 1989;34:258-262. 3. Inoue T, Okumura M.

  33. Inoue TOkumura M. Prognostic significance of parametrial extension in patients with cervical carcinoma stages IB, IIA, and IIB. A study of 628 cases treated by radical hysterectomy and lymphadenectomy with or without postoperative irradiation. Cancer 1984;54:1714-1719.

  34. Sedlis ABundy BNRotman MZLentz SSMuderspach LIZaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. GynecolOncol 1999 may;73(2): 177-83

  35. Rotman MSedlis APiedmonte MRBundy BLentz SSMuderspach LIZaino RJ. A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J RadiatOncolBiol Phys. 2006 May 1;65(1):169-76. Epub 2006 Jan 19.

  36. Twu NFOu YCLiao CIChang WYYang LYTang YHChen TCChen CHChen THYeh LSHsu STChen YCChang CCCheng YMHuang CYLiu FSLin YSHsiao SMKan YYLai CH. Prognostic factors and adjuvant therapy on survival in early-stage cervical adenocarcinoma/adenosquamous carcinoma after primary radical surgery: A Taiwanese Gynecologic Oncology Group (TGOG) study. SurgOncol. 2016 Sep;25(3):229-35.

  37. Juan Zhou, San-Gang Wu, Jia-Yuan Sun, Feng-Yan Li, Huan-Xin Lin, Da-Hong Chen, Zhen-Yu He. The effect of local treatment modalities in patients with early-stage adenocarcinoma of the uterine cervix: a population-based analysis. International Journal of Surgery.

  38. Peter G RoseJames J JavaCharles W. WhitneyFrederick B StehmanRachelle Lanciano, Gillian M Thomas. Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in Gynecologic Oncology Group trials of cisplatin-based chemoradiation. GynecolOncol. 2014 Nov; 135(2): 208–212.

  39. Morris, M., Eifel, P.J., Lu, J. et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para aortic radiation for high-risk cervical cancer.  N. Engl. J. Med. 1999;340:1137–1143.

  40. Peters III WA, Liu PY, Barrett RJ, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J ClinOncol 2000; 18:1606 – 139.

  41. Landoni F, Colombo A, Milani R, Placa F, Zanagnolo V, Mangioni C. Randomized study between radical surgery and radiotherapy for the treatment of stage IB-IIA cervical cancer: 20-year update. J GynecolOncol. 2017 May;28(3):e34.

  42. Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, et al. Randomised study of radical surgery versus radiotherapy for stage IB-IIA cervical cancer. Lancet 1997;350:535-40.

  43. Wagner A, Jhingran A, Gaffney D. Intensity modulated radiotherapy in gynecologic cancers: hope, hype or hyperbole? GynecolOncol 2013;130:229-36.

  44. Baalbergen A, Veenstra Y, Stalpers LL, Ansink AC. Primary surgery versus primary radiation therapy with or without chemotherapy for early adenocarcinoma of the uterine cervix. Cochrane Database Syst Rev 2010:CD006248.

  45. Trifiletti DMSwisher-McClure SShowalter TNHegarty SEGrover S. Postoperative Chemoradiation Therapy in High-Risk Cervical Cancer: Re-evaluating the Findings of Gynecologic Oncology Group Study 109 in a Large, Population-Based Cohort. Int J RadiatOncolBiol Phys. 2015 Dec 1;93(5):1032-44.

  46. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 340:1154-1161, 1999.

  47. NationalComprehensiveCancer Network, NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer v2.2015, Available at:, Accessed: April 9, 2015.

  48. Yamashita H, Okuma K, Kawana K, Nakagawa S, Oda K, Yano T, Kobayashi S, Wakui R, Ohtomo K, Nakagawa, K. Comparison between conventional surgery plus postoperative adjuvantradiotherapy and concurrent chemoradiation for FIGO stage IIB cervicalcarcinoma: a retrospective study. Am J ClinOncol. 2010 Dec;33(6):583-6.

  49. Peter G. Rose, M.D., Brian N. Bundy, PH.D., Edwin B. Watkins, M.D., J. Tate Thigpen, M.D., Gunther Deppe, M.D., Mitchell A. Maiman, M.D., Daniel L. Clarke-Pearson, M.D., Sam Insalaco, M.D.  Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med1999;340:1144-53.

  50. 20.Keys HM,Bundy BM; Stehman FB, Muderspach LIChafe WESuggs CL 3rdWalker JLGersellD.Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999 Apr 15;340(15):1154-61.

  51. Stehman FB1, Ali SKeys HMMuderspach LIChafe WEGallup DGWalker JLGersell D. Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial. Am J Obstet Gynecol. 2007 Nov;197(5):503.e1-6.

  52. Green JAKirwan JMTierney JFSymonds PFresco LCollingwood MWilliams CJ. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001 Sep 8;358(9284):781-6.

  53. Haie-Meder C, Potter R, van Limbergen E, Briot E, De Brabandere M, Dimopoulos J et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group() (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. RadiotherOncol 2005; 74(3):235-245.

  54. Pötter R, Haie-Meder C, Limbergen EV, Barillot I, Brabandere MD, Dimopoulos J et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): Concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. RadiotherOncol 2006; 78(1):67-77.

  55. EMBRACE study.

  56. Fokdal L, Sturdza A, Mazeron R, Haie-Meder C, Tan LT, Gillham C, Šegedin B, Jürgenliemk-Schultz I, Kirisits C, Hoskin P, Pötter R, Lindegaard JC, Tanderup K. Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer: Analysisfrom the retroEMBRACE study.RadiotherOncol. 2016 Sep;120(3):434-440.

  57. Sturdza A, Pötter R, Fokdal LU, Haie-Meder C, Tan LT, Mazeron R, Petric P, Šegedin B, Jurgenliemk-Schulz IM, Nomden C, Gillham C, McArdle O, Van Limbergen E, Janssen H, Hoskin P, Lowe G, Tharavichitkul E, Villafranca E, Mahantshetty U, Georg P, Kirchheiner K, Kirisits C, Tanderup K, Lindegaard JC. Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study.RadiotherOncol. 2016 Sep;120(3):428-433.

  58. ICRU. Prescribing, Recording and Reporting Brachytherapy for Cancer of the Cervix. ICRU Report 88. 2015, in press.

  59. Adhikari P, Vietje P, Mount S. Premalignant and malignant lesions of the vagina. Diagn Histopathology. 2016; 23:28–34.

  60. Hacker NF, Eifel PJ, van der Velden J. Cancer of the vagina. Int J Gynecol Obstet. 2015;131(Suppl.2): S84–87).

  61. Rajaram S, Maheshwari A, Srivastava A. Staging for vaginal cancer. BestPract Res ClinObstetGynaecol. 2015; 29:822–832.

  62. Miyamoto DT, Viswanathan AN. Concurrent chemoradiation for vaginal cancer. PLoS ONE. 2013;8: e65048.

  63. Hacker NF, Eifel PJ, van der Velden J. Cancer of the vulva. Int J Gynecol Obstet. 2015;131(Suppl.2): S76–83.

bottom of page